
Mustafa Khasraw, MD, discusses a follow-up trial to the VERTU study for patient with methylated or unmethylated MGMT glioblastoma who responded well to temozolomide chemotherapy and radiation.

Your AI-Trained Oncology Knowledge Connection!


Mustafa Khasraw, MD, discusses a follow-up trial to the VERTU study for patient with methylated or unmethylated MGMT glioblastoma who responded well to temozolomide chemotherapy and radiation.

Mustafa Khasraw, MD, discusses the purpose II VERTU study and shares key takeaways from his presentation at the 2019 Society for NeuroOncology Annual Meeting.

Published: November 25th 2019 | Updated: